UP!
| Industry | Medical Devices |
|---|---|
| Headquarters | Bethlehem, Pennsylvania, United States |
|
Area served
|
Worldwide |
| Products | OraQuick |
Orasure Technologies is a Bethlehem, Pennsylvania based company in the medical device industry. Their products include diagnostic testing kits. The company had recently developed OraQuick testing kit, the first over-the-counter home HIV test.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-09 | -0.26 | -0.26 |
| Q1 2022 | 2022-05-10 | -0.28 | -0.28 |
| Q4 2021 | 2022-02-23 | -0.14 | -0.14 |
| Q3 2021 | 2021-11-03 | -0.21 | -0.21 |
| Q2 2021 | 2021-08-03 | -0.02 | -0.02 |
| Q1 2021 | 2021-05-05 | 0.05 | 0.05 |
| Q4 2020 | 2021-03-01 | 0.03 | 0.03 |
| Q3 2020 | 2020-11-04 | 0.01 | 0.01 |
| Q2 2020 | 2020-08-05 | -0.16 | -0.16 |
| 2016-07-05 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2016-07-05 | Reiterated Rating | Mizuho | Outperform | $8.00 |
| 2016-06-29 | Reiterated Rating | BTIG Research | Buy | $9.00 |
| 2016-06-13 | Downgrade | Raymond James | Outperform to Market Perform | $8.00 |
| 2016-06-13 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform | $8.00 |
| 2016-05-06 | Reiterated Rating | Mizuho | Buy | $8.00 |
| 2016-03-18 | Reiterated Rating | Canaccord Genuity | Buy | $9.00 |
| 2016-02-05 | Reiterated Rating | Mizuho | Buy | |
| 2016-02-04 | Reiterated Rating | Canaccord Genuity | Buy | $8.00 |
| 2016-02-04 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2015-12-14 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2015-11-11 | Lower Price Target | Canaccord Genuity | Buy | $9.00 to $8.00 |
| 2015-11-05 | Boost Price Target | Mizuho | Buy | $8.00 to $12.00 |
| 2015-08-10 | Reiterated Rating | Canaccord Genuity | Buy | $11.00 to $9.00 |
| 2015-08-06 | Lower Price Target | Jefferies Group | Buy | $9.00 to $8.00 |
| 2015-06-17 | Reiterated Rating | Jefferies Group | Buy to Buy | $9.00 |
| 2015-05-10 | Reiterated Rating | Raymond James | Outperform | $11.00 to $8.00 |
| 2015-05-07 | Lower Price Target | Canaccord Genuity | Buy | $13.00 to $11.00 |
| 2015-05-07 | Lower Price Target | Jefferies Group | Buy | $12.00 to $9.00 |
| 2015-05-07 | Downgrade | JMP Securities | Outperform to Market Perform | $10.00 |
| 2015-02-05 | Reiterated Rating | Canaccord Genuity | Buy | $13.00 |
| 2015-01-23 | Reiterated Rating | Mizuho | Buy | $10.00 to $12.00 |
| 2014-12-31 | Boost Price Target | Jefferies Group | Buy | $10.00 to $12.00 |
| 2014-12-23 | Boost Price Target | Canaccord Genuity | Top Pick to Buy | $13.00 to $14.00 |
| 2014-10-16 | Reiterated Rating | Canaccord Genuity | Buy | $11.00 to $12.00 |
| 2014-06-12 | Boost Price Target | Canaccord Genuity | Buy | $10.00 to $11.00 |
| 2014-06-12 | Reiterated Rating | Jefferies Group | Buy | $9.00 to $10.00 |
| 2014-06-12 | Boost Price Target | Raymond James | $8.50 to $9.00 | |
| 2014-06-11 | Boost Price Target | Mizuho | Buy | $9.00 to $10.00 |
| 2014-05-08 | Reiterated Rating | Raymond James | Outperform | $10.00 to $8.50 |
| 2014-05-02 | Boost Price Target | Cowen and Company | $8.00 to $9.00 | |
| 2014-03-06 | Boost Price Target | Raymond James | $7.50 to $10.00 | |
| 2014-01-03 | Reiterated Rating | Jefferies Group | Buy | $9.00 |
| 2013-11-26 | Lower Price Target | Cowen and Company | $8.00 to $7.00 | |
| 2013-11-22 | Reiterated Rating | Cowen and Company | Buy | $8.00 |
| 2013-11-22 | Boost Price Target | Jefferies Group | $8.00 to $9.00 | |
| 2013-11-07 | Downgrade | Stephens | Overweight to Equal Weight | |
| 2013-10-04 | Boost Price Target | Cowen and Company | Outperform | $6.60 to $8.00 |
| 2013-09-19 | Upgrade | Raymond James | Market Perform to Outperform | $8.00 |
| 2012-12-21 | Initiated | Mizuho | Buy | $9 |
| 2012-08-08 | Upgrade | Barrington Research | Mkt Perform to Outperform | $12.50 |
| 2012-07-05 | Downgrade | Barrington Research | Outperform to Mkt Perform | |
| 2012-03-27 | Initiated | JMP Securities | Mkt Outperform | $15 |
| 2012-03-21 | Upgrade | MLV & Co | Hold to Buy | $11 to $13 |
| 2012-02-09 | Downgrade | MLV & Co | Buy to Hold | $11 |
| 2011-07-01 | Resumed | Barrington Research | Outperform | $10 |
| 2010-11-30 | Initiated | Barrington Research | Outperform | $8 |
| 2009-11-17 | Upgrade | Needham | Hold to Buy | $5.50 |
| 2008-06-20 | Downgrade | Needham | Buy to Hold | |
| 2008-05-07 | Reiterated | Susquehanna Financial | Positive | $12 to $10 |
| 2008-05-07 | Reiterated | Needham | Buy | $14 to $10 |
| 2008-02-13 | Reiterated | Lazard Capital | Buy | $15 to $14 |
| 2007-12-19 | Initiated | Pacific Growth Equities | Buy | |
| 2007-10-15 | Reiterated | Needham & Co | Buy | $10 to $14 |
| 2007-07-09 | Reiterated | Lazard Capital | Buy | $12 to $15 |
| 2016-07-05 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2016-07-05 | Reiterated Rating | Mizuho | Outperform | $8.00 |
| 2016-06-29 | Reiterated Rating | BTIG Research | Buy | $9.00 |
| 2016-06-13 | Downgrade | Raymond James | Outperform to Market Perform | $8.00 |
| 2016-06-13 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform | $8.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In OSUR 158 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 13.40M |
| Vanguard Group, Inc | 5.12M |
| Camber Capital Management LLC | 4.25M |
| Neuberger Berman Group LLC | 2.95M |
| STATE STREET CORP | 2.59M |
| AMERICAN CAPITAL MANAGEMENT INC | 2.51M |
| WADDELL & REED FINANCIAL INC | 2.45M |
| DIMENSIONAL FUND ADVISORS LP | 2.24M |
| BlackRock Fund Advisors | 1.96M |
| RENAISSANCE TECHNOLOGIES LLC | 1.82M |
| BLACKROCK ADVISORS LLC | 1.60M |
| BlackRock Institutional Trust Company, N.A. | 1.55M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.31M |
| KENNEDY CAPITAL MANAGEMENT, INC. | 1.11M |
| MORGAN STANLEY | 1.06M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Michels Douglas A President & CEO | 1.18% (660861) | OSUR / WST / |
| WATSON DOUGLAS G | 0.35% (196879) | DCTH / DNDN / OSUR / WMGI / |
| SPAIR RONALD H COO & CFO | 0.30% (166402) | FULT / OSUR / |
| Zezzo II Anthony EVP, Marketing and Sales | 0.27% (148383) | OSUR / |
| TANG STEPHEN S PHD | 0.13% (73532) | OSUR / |
| PRINGLE ROGER L | 0.13% (72591) | OSUR / |
| Patrick Charles W | 0.10% (58182) | OSUR / |
| JERRETT JACK E SVP & General Counsel | 0.09% (50268) | OSUR / |
| KUNA MARK L SVP. & Controller | 0.09% (49213) | OSUR / |
| Celano Michael | 0.07% (41128) | OSUR / REPH / |
| OSTROV GERALD M | 0.07% (39346) | ORMP / OSUR / |
| REED MICHAEL SVP R&D and CSO | 0.05% (30085) | OSUR / |
| Lee Stephen R Exec. VP & CSO | 0.03% (19476) | OSUR / |
| SMITH BRIAN SEE REMARKS | 0.03% (18075) | OSUR / |
| HOBBS EAMONN P | 0.03% (14711) | ATRS / DCTH / OSUR / |
| WHITTERS ERIC SVP, Research and Development | 0.02% (9857) | OSUR / |
| LANCASTER RONNY B | 0.01% (6295) | OSUR / |
| Aspinall Mara G. | 0.01% (5000) | MDRX / OSUR / SFE / |
UM